SDZNY or ZTS: Which Is the Better Value Stock Right Now?

An analysis comparing Sandoz Group AG (SDZNY) and Zoetis (ZTS) for value investors identifies SDZNY as the preferred option within the Medical - Drugs sector. SDZNY holds a stronger Zacks Rank of #2 (Buy) versus ZTS's #3 (Hold), reflecting more favorable earnings estimate revisions. Furthermore, SDZNY exhibits more attractive valuation metrics, including a lower forward P/E (18.94 vs. 24.45), a significantly lower PEG ratio (1.05 vs. 2.50), and a lower P/B ratio (3.35 vs. 13.81), resulting in a 'B' Value grade compared to ZTS's 'C'.

Analysis

A comparative analysis of Sandoz Group AG (SDZNY) and Zoetis (ZTS) within the Medical-Drugs sector identifies SDZNY as the more favorable option for value-oriented investors. This conclusion is supported by the Zacks Rank system, which assigns SDZNY a #2 (Buy) rating, indicating a more positive trend in earnings estimate revisions compared to ZTS's #3 (Hold) rating. On a quantitative valuation basis, SDZNY trades at a significant discount to ZTS across multiple key metrics. Specifically, SDZNY has a forward P/E ratio of 18.94 versus 24.45 for ZTS. The disparity is more pronounced in growth-adjusted valuation, where SDZNY's PEG ratio is 1.05, substantially lower than ZTS's 2.50. Furthermore, SDZNY's price-to-book (P/B) ratio of 3.35 is considerably more attractive than ZTS's P/B of 13.81. These factors culminate in a superior 'B' grade for Value in the Zacks Style Scores system for SDZNY, while ZTS receives a 'C'.

Key Decisions for Investors

• Value-focused investors should consider Sandoz Group AG (SDZNY) over Zoetis (ZTS) given its more attractive valuation metrics, including a significantly lower PEG ratio of 1.05 and P/B ratio of 3.35.
• The superior Zacks Rank of #2 (Buy) for SDZNY suggests a stronger analyst outlook based on positive earnings estimate revisions, providing a potential catalyst for the stock.
• Investors holding or considering Zoetis (ZTS) should be mindful of its relatively high valuation, as indicated by its P/E of 24.45 and PEG of 2.50, which may limit near-term upside compared to more favorably priced peers.